August 23, 2017 9:30 PM ET

Pharmaceuticals

Company Overview of Nektar Therapeutics

Executive Profile

Lutz Lingnau

Independent Director, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 6 different industries.

See Board Relationships
74$417,762

Background

Mr. Lutz Lingnau is a Board Observer of Evestra, Inc. Mr. Lingnau served as the Chief Executive Officer and President of Schering Berlin, Inc. He held this position from 1989 to his retirement in 2005. He joined Schering AG's business trainee program in 1966. From 1968 to 1989, he served in various capacities at Schering AG and in a number of subsidiaries in South America and the United States, including as President of Berlex Laboratories, Inc., from 1983 to 1985, as ...

Corporate Headquarters

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships

2007-Present
Independent Director

Education

There is no Education data available.

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$80,250
Total Calculated Compensation$417,762
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Mark R. Baker J.D.Chief Executive Officer and Director
Progenics Pharmaceuticals, Inc.
$646.8K
Craig Alexander Collard Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Michael T. Heffernan B.S. Pharm, R.Ph.Founder, Chairman, Chief Executive Officer, President, Treasurer and Secretary
Collegium Pharmaceutical, Inc.
$502.8K
Daniel J. Abdun-Nabi Chief Executive Officer, President and Director
Emergent BioSolutions Inc.
$776.6K
Stephen J. Farr Ph.D.Co-Founder, Chief Executive Officer, President and Director
Zogenix, Inc.
$468.8K
Compensation as of Fiscal Year 2016.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nektar Therapeutics, please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.